CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that extends the half-life of natural GHRH from about 7 minutes to roughly 8 days when bound to drug affinity complex (DAC) technology. It was originally developed by ConjuChem in the mid-2000s as a candidate therapy for growth hormone deficiency, lipodystrophy, and muscle wasting conditions. Phase 1 and Phase 2 trials were published in The Journal of Clinical Endocrinology and Metabolism between 2005 and 2006.<\/p>\n
The drug never reached FDA approval. ConjuChem halted development after a patient death during a separate Phase 2 trial for lipodystrophy, and the compound has lived in research and gray-market peptide spaces ever since. Today CJC-1295 is sold by compounding pharmacies and research peptide suppliers in two main forms, with DAC and without DAC, often paired with ipamorelin or another growth hormone secretagogue.<\/p>\n
This guide pulls together the published human data, the dosing protocols used in clinical trials, the documented side effects, and the gaps where research simply doesn’t exist yet. If you’re considering CJC-1295 for body composition, recovery, or longevity, you should know what the evidence supports and what it doesn’t.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
CJC-1295 is a 30-amino-acid peptide modeled on the first 29 amino acids of human GHRH, with four amino acid substitutions and a maleimidopropionic acid (MPA) group that lets it bind covalently to albumin in the bloodstream.<\/strong> The albumin binding is what gives it the long half-life. Without the DAC modification, the modified GHRH analog has a half-life closer to 30 minutes and is often sold as “mod GRF 1-29” or “CJC-1295 no DAC.”<\/p>\n Quick Answer: CJC-1295 with DAC has a half-life of about 8 days, allowing weekly dosing (Teichman et al. 2006, JCEM)<\/p>\n ConjuChem licensed the technology from researchers at the University of Saskatchewan in the early 2000s. The published Phase 1 trial by Teichman et al. enrolled 21 healthy adults aged 21 to 61 and tested single subcutaneous doses ranging from 30 to 250 mcg\/kg. The Phase 2 trial in HIV-associated lipodystrophy followed in 2006 with weekly dosing for 12 weeks.<\/p>\n After the development program collapsed, the molecule remained available through compounding channels and research peptide vendors. It has no approved indication in any country.<\/p>\n CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, stimulating pulsatile release of endogenous growth hormone.<\/strong> Unlike direct GH injection, this mechanism preserves the body’s natural feedback loop, so somatostatin can still suppress GH release when IGF-1 rises too high.<\/p>\n In the Teichman Phase 1 trial, a single 60 mcg\/kg subcutaneous injection raised mean GH concentrations 2 to 10 fold above baseline, and the elevation persisted for about 6 days. IGF-1 climbed 1.5 to 3 fold above baseline and stayed elevated for 9 to 11 days. Higher doses produced larger and longer responses but also more side effects.<\/p>\n The mechanism matters because chronic high IGF-1 is associated with increased risk of certain cancers in epidemiological data. Boyd et al. 2008 in the International Journal of Cancer reported that men in the highest IGF-1 quintile had roughly double the prostate cancer risk of men in the lowest quintile. This is a key reason endocrinologists are cautious about long-term GH or GHRH analog use outside diagnosed deficiency.<\/p>\n Published human body composition data on CJC-1295 specifically is thin.<\/strong> The 2006 ConjuChem Phase 2 trial in HIV lipodystrophy reported modest reductions in visceral adipose tissue and small gains in lean mass over 12 weeks of weekly dosing, but full results were never published in a peer-reviewed journal after the program was discontinued.<\/p>\n Most claims about CJC-1295 body composition effects extrapolate from tesamorelin trials. Tesamorelin is a similar GHRH analog that was FDA-approved in 2010 for HIV-associated lipodystrophy. The Falutz et al. 2007 NEJM trial showed tesamorelin reduced visceral adipose tissue by about 15 percent over 26 weeks compared with placebo. Lean mass increased about 1.3 kg. Total body fat did not change significantly.<\/p>\n These are real numbers from a real trial, but they come from a different drug in a specific disease population. Healthy adults using CJC-1295 for cosmetic body composition goals are operating outside the published evidence base.<\/p>\n Clinical trial dosing used 30 to 250 mcg\/kg subcutaneously once weekly.<\/strong> For an 80 kg adult that translates to 2.4 to 20 mg per dose. Real-world peptide protocols sold by compounding pharmacies typically use much smaller fixed doses, often 1 to 2 mg per week of CJC-1295 with DAC, or 100 to 300 mcg once or twice daily of the no-DAC version.<\/p>\n The no-DAC version is typically dosed at bedtime to mimic the natural GH pulse that occurs during early slow-wave sleep. When paired with ipamorelin, a common protocol is 100 to 300 mcg of each peptide subcutaneously 30 minutes before sleep, five days on and two days off, for 8 to 12 week cycles.<\/p>\n None of these protocols come from controlled trials. They reflect prescriber convention and bodybuilding community practice rather than published dose-finding studies in healthy adults.<\/p>\n The Teichman 2006 trial reported injection site reactions in 80 percent of subjects, transient flushing, headache, and mild nausea.<\/strong> At doses of 125 mcg\/kg or higher, several subjects developed sustained elevations in IGF-1 above the upper limit of normal, which is the laboratory signal for acromegaly risk.<\/p>\n Longer-term concerns include fluid retention, carpal tunnel symptoms, insulin resistance, and joint pain, all of which are documented in patients receiving recombinant GH therapy and would be expected with any agent that raises GH and IGF-1 chronically. The Cohn et al. 1993 Annals of Internal Medicine study of GH in healthy older men reported these complications at rates of 24 to 46 percent over six months.<\/p>\n Cancer risk is the largest unknown. No long-term cancer surveillance data exists for CJC-1295 because no trial has run long enough to generate it.<\/p>\n CJC-1295 is not FDA-approved for any indication.<\/strong> It can be legally compounded by 503A and 503B pharmacies for individual patients under a prescription from a licensed physician, but the FDA placed CJC-1295 on the list of substances that may not be compounded under section 503A in 2023 pending further safety review. The legal status is in flux as of 2026.<\/p>\n Buying CJC-1295 from research peptide websites for personal use sits in a gray zone. These products are labeled “not for human consumption” and sold for research purposes only. WADA banned the substance for athletic competition in 2014, and it shows up on most major sports drug screens.<\/p>\n If you want to use CJC-1295 legally, you need a prescription from a physician who works with a licensed compounding pharmacy that still produces it.<\/p>\n Key Takeaway: IGF-1 levels rose 1.5 to 3 fold and remained elevated for 9 to 11 days after a single dose<\/p>\n In the United States, CJC-1295 is most commonly prescribed by anti-aging clinics, functional medicine practitioners, and some endocrinologists for adults with suboptimal but not deficient GH levels.<\/strong> The target patient is typically over 40, complaining of fatigue, poor recovery, increased visceral fat, or sleep disruption, with an IGF-1 in the lower half of the age-adjusted range.<\/p>\n Insurance does not cover it. Out-of-pocket cost for a 12-week protocol typically runs 400 to 1,200 dollars depending on the pharmacy, the specific compound, and whether it’s paired with ipamorelin or another secretagogue.<\/p>\n This is a different patient population from FDA-approved GH therapy, which requires documented adult GH deficiency on stimulation testing.<\/p>\n Sermorelin is the original GHRH 1-29 analog, FDA-approved in 1990 for pediatric GH deficiency and later for adult use, though manufacturing has been discontinued.<\/strong> Half-life is about 10 to 20 minutes. Tesamorelin is a stabilized version with a half-life of about 26 minutes, FDA-approved in 2010 for HIV lipodystrophy.<\/p>\n CJC-1295 with DAC is the longest-acting of the three at roughly 8 days. The trade-off is that you can’t titrate quickly if IGF-1 climbs too high, because the drug stays in the system for over a week.<\/p>\n For most clinical purposes where a GHRH analog is appropriate, tesamorelin has the strongest evidence base and FDA backing. CJC-1295 has the convenience of weekly dosing and lower cost in compounded form.<\/p>\n CJC-1295 is not a weight loss drug in the same category as GLP-1 medications like semaglutide or tirzepatide.<\/strong> The SURMOUNT-1 trial of tirzepatide (Jastreboff et al. 2022 NEJM) produced 20.9 percent weight loss at 72 weeks. STEP 1 (Wilding et al. 2021 NEJM) showed 14.9 percent with semaglutide. CJC-1295 has no comparable data.<\/p>\n What CJC-1295 may do is shift body composition modestly toward more lean mass and less visceral fat, based on the tesamorelin analog data. Total body weight often doesn’t change much. For someone primarily trying to lose weight, GLP-1 therapy through a personalized treatment plan is a far better evidence-supported path. TrimRx offers a free assessment quiz for patients exploring compounded semaglutide and tirzepatide options.<\/p>\n Honestly, we don’t know.<\/strong> The longest published human trial of CJC-1295 ran 28 days. We have no data on what happens after 6 months, 2 years, or 10 years of weekly use. Animal carcinogenicity studies were never publicly released after development stopped.<\/p>\n The relevant comparison points are recombinant human GH in adults without deficiency. The Liu et al. 2007 Annals of Internal Medicine meta-analysis of GH in healthy older adults found increased rates of soft tissue edema, joint pain, carpal tunnel syndrome, and glucose intolerance, with no clear benefit on functional outcomes. The cancer signal in long-term GH-treated populations is mixed but concerning enough that most endocrinologists treat chronic GH elevation outside diagnosed deficiency as a meaningful risk.<\/p>\n If you’re considering long-term CJC-1295, you should be monitoring IGF-1, fasting glucose, HbA1c, and getting age-appropriate cancer screening. A prescriber who doesn’t insist on this is not practicing carefully.<\/p>\n Bottom line: No long-term safety data exists beyond about 28 days of human exposure<\/p>\n Growth hormone elevation begins within hours of injection. IGF-1 rises gradually over 2 to 4 days and peaks around day 5 to 7 after a single dose, based on the Teichman 2006 Phase 1 data. Subjective effects like sleep quality changes are often reported in the first 1 to 2 weeks, though no controlled trials have measured these outcomes.<\/p>\n The Phase 1 trial included both men and women. There’s no specific contraindication in females, but pregnant and breastfeeding women should not use it given the absence of safety data and the role of IGF-1 in fetal growth.<\/p>\n We don’t have direct evidence that it does. We also don’t have data ruling it out. Sustained IGF-1 elevation is associated with higher rates of prostate, breast, and colorectal cancers in observational studies. Anyone with a personal or strong family history of these cancers should think hard before using a drug that raises IGF-1 for months at a time.<\/p>\n DAC is drug affinity complex, the chemical group that binds the peptide to albumin and extends its half-life from 30 minutes to 8 days. With DAC means weekly dosing and sustained GH elevation. Without DAC means daily or twice-daily dosing and pulsatile GH release that more closely mimics natural physiology. Many prescribers prefer no-DAC for that reason.<\/p>\n Yes, this is the most common pairing in real-world protocols. Ipamorelin is a ghrelin mimetic that stimulates GH release through a different receptor, so the two have additive effects. The combination is sold under various brand names by compounding pharmacies and is the basis of most peptide therapy protocols marketed for body composition.<\/p>\n Common protocols use 8 to 12 weeks on followed by 4 weeks off, though this convention isn’t supported by trial data. The rationale is to allow the pituitary feedback loop to reset and to limit sustained IGF-1 elevation. Whether cycling actually reduces long-term risk is unknown.<\/p>\n No. Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity, with extensive FDA approval and trial data. CJC-1295 is a GHRH analog with no FDA approval and limited published evidence. They work through completely different mechanisms and treat different conditions. If your goal is weight loss, semaglutide or tirzepatide has far stronger support.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n <\/p>\n Introduction CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that extends the half-life of natural GHRH from about 7 minutes to…<\/p>\n","protected":false},"author":11,"featured_media":92656,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"CJC-1295 Complete Guide: Benefits, Dosing, Side Effects & Research","_yoast_wpseo_metadesc":"CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that extends the half-life of natural GHRH from about 7 minutes to roughly 8...","_yoast_wpseo_focuskw":"cjc 1295 complete","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[25,40,41],"class_list":["post-89255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity","tag-dosing","tag-peptides","tag-research"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89255"}],"version-history":[{"count":4,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89255\/revisions"}],"predecessor-version":[{"id":93657,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89255\/revisions\/93657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92656"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Does CJC-1295 Affect Growth Hormone and IGF-1?<\/h2>\n
What Body Composition Changes Does CJC-1295 Produce?<\/h2>\n
What Is the Standard CJC-1295 Dosing Protocol?<\/h2>\n
What Are the Documented Side Effects of CJC-1295?<\/h2>\n
Is CJC-1295 Legal to Buy and Use?<\/h2>\n
Who Actually Prescribes CJC-1295 and for What?<\/h2>\n
How Does CJC-1295 Compare with Tesamorelin and Sermorelin?<\/h2>\n
What About CJC-1295 and Weight Loss?<\/h2>\n
What Does the Long-term Safety Picture Look Like?<\/h2>\n
FAQ<\/h2>\n
How Fast Does CJC-1295 Work?<\/h3>\n
Can Women Use CJC-1295?<\/h3>\n
Does CJC-1295 Cause Cancer?<\/h3>\n
What’s the Difference Between CJC-1295 with DAC and Without DAC?<\/h3>\n
Can I Stack CJC-1295 with Ipamorelin?<\/h3>\n
How Often Should I Cycle Off CJC-1295?<\/h3>\n
Is CJC-1295 the Same as Ozempic\u00ae or Semaglutide?<\/h3>\n
Related Articles<\/h2>\n
\n